After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual ...

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on ...

The vaccine will only be available to those at high risk from Covid—excluding those who may need it to protect a relative or ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax (NVAX) stock in focus as the U.S. FDA approves its COVID-19 vaccine Nuvaxovid for high-risk groups in the U.S. Read ...

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2025. Novavax, Inc. (Nasdaq: NVAX) today announced that it will ...